Bioptigen

Bioptigen

Optical Coherence Tomography (OCT): Leica Microsystems. Learn more

Launch date
Market cap
-
Enterprise valuation
$6—9m (Dealroom.co estimates Mar 2011.)
Durham North Carolina (HQ)
  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

$1.5m

Early VC

N/A

Acquisition
Total Funding$1.5m

Recent News about Bioptigen

Edit
More about Bioptigeninfo icon
Edit

Bioptigen, a subsidiary of Leica Microsystems, specializes in providing advanced imaging solutions for both life science research and industrial applications. The company offers a range of high-performance microscopes and imaging systems designed to support scientific research, including cancer research, cell culture, neuroscience, and live cell imaging. In the industrial sector, Bioptigen's products help minimize downtime and enhance manufacturing processes through precise visualization and measurement tools. The business model revolves around selling these sophisticated imaging systems and providing expert local support to ensure optimal performance. Bioptigen serves a diverse clientele, including academic institutions, research laboratories, and manufacturing companies, operating in a global market. Revenue is generated through the sale of imaging equipment, maintenance services, and technical support.

Keywords: advanced imaging, life science, industrial applications, microscopy, digital imaging, cancer research, neuroscience, cell culture, manufacturing, technical support.